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Abstract
Protein modifications of death receptor pathways play a central role in the regulation of apoptosis. It has been
demonstrated that O-glycosylation of TRAIL-receptor (R) is essential for sensitivity and resistance towards TRAIL-mediated
apoptosis. In this study we ask whether and how glycosylation of CD95 (Fas/APO-1), another death receptor, influences
DISC formation and procaspase-8 activation at the CD95 DISC and thereby the onset of apoptosis. We concentrated on N-
glycostructure since O-glycosylation of CD95 was not found. We applied different approaches to analyze the role of CD95 N-
glycosylation on the signal transduction: in silico modeling of CD95 DISC, generation of CD95 glycosylation mutants (at
N136 and N118), modulation of N-glycosylation by deoxymannojirimycin (DMM) and sialidase from Vibrio cholerae (VCN).W e
demonstrate that N-deglycosylation of CD95 does not block DISC formation and results only in the reduction of the
procaspase-8 activation at the DISC. These findings are important for the better understanding of CD95 apoptosis
regulation and reveal differences between apoptotic signaling pathways of the TRAIL and CD95 systems.
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Introduction
Apoptotic cell death is common in multicellular organisms and
can be triggered by a number of factors including UV- or c-
irradiation, chemotherapeutic drugs and signaling from death
receptors [1]. CD95 (APO-1/Fas) is a member of the death
receptor family, a subfamily of the TNF-R superfamily [2].
Crosslinking of CD95 with its natural ligand CD95L (CD178) [3]
or with agonistic antibodies such as anti-APO-1 induces apoptosis
in sensitive cells [4]. In addition, triggering of CD95 induces a
number of non-apoptotic activities [1,5,6].
The death-inducing signaling complex (DISC) is formed within
seconds after CD95 stimulation [7]. The DISC consists of
oligomerized CD95, the adaptor molecule FADD, two isoforms
of procaspase-8 (procaspase-8/a and procaspase-8/b), procaspase-
10 and c-FLIPL/S/R [1,8,9,10]. The interactions between the
molecules at the DISC are based on homotypic contacts. The
death domain (DD) of the receptor interacts with the DD of
FADD, while the death effector domain (DED) of FADD interacts
with the N-terminal tandem DEDs of procaspases-8, -10 and c-
FLIPL/S/R. Procaspase-8 upon binding to the DISC undergoes
oligomerization that results in processing of the zymogen, for
which a two-step mechanism has been described. The first
cleavage step generates the two subunits p43/p41 and p12 [11].
In a second cleavage step, the active enzyme subunits p18, p10
and the prodomains p26/p24 are produced. As a result the active
caspase-8 heterotetramer p102–p182 is released into the cytosol to
propagate the apoptotic signal [12]. The initial events of DISC
formation and caspase-8 activation have not been clarified yet.
Pre-oligomerization of CD95 via the Pre-Ligand Assembly
Domain (PLAD) has been suggested to play an important role in
apoptosis initiation [13]. Recently, there have been several new
reports on X-ray structure of CD95 and FADD [14,15,16].
Although the reported X-ray structures contradict each other/are
in disagreement in terms of the CD95/FADD structure, they
provide a basis for consideration of the initial events preceeding
caspase-8 binding and activation at the DISC.
Two CD95 signaling pathways have been identified so far [17].
Type I cells are characterized by high levels of CD95 DISC
formation and increased amounts of active caspase-8 which
activates downstream effector caspases-3 and -7. Type II cells are
characterized by lower levels of CD95 DISC formation and, thus,
lower levels of active caspase-8. In this case, signaling requires an
additional amplification loop that involves the cleavage of the Bcl-
2-family protein Bid by caspase-8 to generate truncated (t)Bid and
subsequent (t)Bid-mediated release of cytochrome C from
mitochondria. The release of cytochrome C from mitochondria
results in apoptosome formation followed by activation of
procaspase-9, which in turn cleaves downstream effector caspases.
CD95 is a glycosylated type I transmembrane receptor
(Figure 1A) and has been reported to be N-glycosylated in
its extracellular domain [18,19,20]. N-linked glycosylation is
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endoplasmic reticulum (ER) and involves the transfer of a
carbohydrate moiety to an asparagine residue within a specific
amino acid consensus sequence. In addition, CD95 was reported
to be sialylated on the N-linked oligosaccharide chains [18,19].
Sialic acids are a diverse family of sugar units with a nine-carbon
backbone that are typically attached to the outermost ends of
glycans [21,22]. Sialylation is mainly regulated by sialidases and
sialyltransferases, which cleave sialic acid residues from and
transfer them to glycoconjugates, respectively [23]. It has been
reported previously that desialylation of CD95 using Vibrio cholerae
neuraminidase (VCN) results in increased sensitivity towards CD95-
induced apoptosis [18,19].
Glycosylation has been reported to play an important role in the
modulation of the sensitivity towards death receptor-induced
apoptosis. It has been reported that O-glycosylation of TRAIL-R
is a major factor for the apoptosis induction. Further O-
glycosylation promoted ligand-stimulated clustering of TRAIL-
R1 and TRAIL-R2, which mediates recruitment and activation of
procaspase-8 [24]. In this line, the aim of this study was to analyze
the influence of CD95 glycosylation on apoptosis initiation and
procaspase-8 activation at the DISC. Using amino acid sequence
information and bioinformatic analysis we predicted that CD95 is
N-glycosylated at N118 and N136. Furthermore, by means of in
silico three-dimensional (3D) modeling we tentatively predict the
possible mechanism of how N-glycosylation might influence DISC
formation and procaspase-8 activation at the DISC. Surprisingly,
on the experimental level, we could only find that deglycosylation
of CD95 leads to the slowing down of procaspase-8 activation at
the DISC. Notably, the formation of the DISC, e.g. the
recruitment of FADD to the DISC was not blocked. The
sensitisation upon CD95 N-deglycosylation took place only upon
a narrow range of concentrations of CD95 antagonists. This
demonstrated that, in contrast to the TRAIL-R O-linked glycan
moiety, the CD95 N-glycan structure contributes to a smaller
extent to the initiation of the apoptotic signaling leading to the
death of the cells.
Results
Analysis of CD95 glycosylation using bioinformatic
analysis and in silico 3D modeling
CD95 has been described to be an N-glycosylated protein [18].
To characterize CD95 N-glycosylation putative glycosylation sites
of human CD95 were analyzed using bioinformatic analysis
(Figure 1). The presence of several glycosylation sites was
predicted, which is in accordance with previous reports and
supports N-glycosylation of CD95 [20]. There are three N-
glycosylation sites predicted (Figure 1B). Two N-X-S/T sites are
located in the extracellular domains (residues 112–149) at positions
N118 and N136 and one in the intracellular domain (174–298) at
position N223 (Figure 1B). Predictions also show the presence of
one O-glycosylation site at T214, which is highly unlikely as it is
located in the CD95 intracellular domain (Figure 1C).
Analysis of an alignment of 16 sequences of CD95 from
different species showed that the Asn residue in the first N-
glycosylation site, which corresponds to N118 in human CD95, is
the most conserved one. The Asn residue in the second N-
glycosylation site, which corresponds to N136 in human CD95, is
less conserved with regard to glycosylation (Figure S1A).
Moreover, the N-X-S/T sequence of the second N-glycosylation
site N136 is conserved in three organisms from all 16 analyzed,
suggesting N136 residue could be potentially glycosylated (Figure
S1B).
To analyze the possible role of CD95 glycans in the CD95
DISC formation and in the formation of the CD95 DISC complex
network on the membrane in silico modeling was applied. Core
structures of N-glycans were added using the GlyProt tool as
presented in Figure S2A. It is generally accepted that CD95 DISC
core structures are composed of three molecules of CD95 and
three molecules of CD95L [16]. As depicted in Figure 2, upon
formation of CD95 DISC core structure, the glycan attached to
N136 of CD95 could potentially be important for complex
formation and/or stability, due to its close proximity to CD95L
molecule (Figure 2A, B) and could form an extensive hydrogen
bond network with residues 200–204 of CD95L (Figure 2C). The
glycan attached to N118 of CD95 most probably is not important
for the formation and/or stability of the CD95 DISC core
structure as it is located more distal from the CD95-CD95L
interface (Figure 2B). On the other hand, the glycan attached to
N118 of CD95 could be important for the stabilization of the
DISC-DISC interaction upon formation of the CD95 DISC
network. Oligomerisation of procaspase-8 might occur more
efficiently and lead to more efficient procaspase-8 activation at
the CD95 DISC network in the presence of CD95 glycans at
N118. In this way, the modeling predicted a possible function of
CD95 N-glycosylation for the proper caspase-8 activation
(Figure 2D). We subsequently sought to validate the predictions
of this modeling approach by further biochemical analysis.
Figure 1. CD95 is a predicted glycoprotein. (A) Schematic
representation of domain organization of CD95. The CRD are shown
in yellow, the transmembrane domain (TM) in blue, the DD in red.
Potential glycosylation sites are depicted as schematic oligosaccharides,
phosphorylation sites as black arrows, palmitoylation sites as green
arrows. (B) and (C) Prediction of N- and O-linked glycosylation sites in
CD95. Graphical representation of prediction with indicated scores
generated by server.
doi:10.1371/journal.pone.0019927.g001
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To validate the bioinformatic predictions using biochemical
analysis we sought to demonstrate that CD95 in our cell lines is
indeed N-glycosylated. We compared CD95 in cellular lysates of
different human T and B cell lines using anti-CD95 antibodies
[25]. Interestingly, we observed that CD95 in B lymphoblastoid
SKW6.4 and T leukaemia Hut78 cells appeared as two bands
which are not the result of alternative splicing as assessed by RT-
PCR (data not shown), while CD95 in T leukaemia cells J16
appeared as a single band on 10% SDS-PAGE (Figure 3A). The
bands of CD95 had a diffuse and broad shape, which is
characteristic for glycosylated proteins analyzed by Western Blot.
To confirm N-glycosylation of CD95 we used N-glycosidase F, the
enzyme, which cleaves off complete N-glycan moieties from a
given protein (Figure S2B). The treatment with N-glycosidase F
resulted in a clear shift of two major bands in case of SKW6.4 cells
to a lower molecular mass range (Figure 3B). The one major band
in case of J27 and JA3 cells also shifted to the lower molecular
mass (Figure 3B). Therefore, we concluded that CD95 is N-
glycosylated in all cell lines analyzed.
To confirm N-glycosylation of CD95 at the predicted glyco-
sylation sites we generated CD95 single and double ‘glycomutants’
by site-directed mutagenesis (Figure 4A). Although glycan addition
at the intracellular consensus site is highly unlikely, it was
nevertheless included as a negative control for mutagenesis.
Transient overexpression of these mutants in HeLa cells
demonstrated that only glycomutants at positions N118 and
N136 show characteristic CD95 band shifts to the lower molecular
mass upon Western Blot analysis (Figure 4B). These changes in
molecular mass, indicating a possible impaired glycosylation, were
observed for single mutants N118Q and N136Q as well as for all
double mutants containing N118Q and/or N136Q (Figure 4B).
There were no CD95 bands shifts in case of the N223Q and
T214Q mutants (Figure 4B). This demonstrates that there is no O-
or N-glycosylation at the predicted sites in the intracellular domain
of CD95 as expected. The treatment of all mutants with N-
glycosidase F resulted in the characteristic shift of CD95 bands to
the lower molecular mass (Figure 4C). Importantly, the introduc-
tion of the mutations at the glycosylation sites did not block
transport of CD95 to the cell surface as monitored by flow
cytometry cell surface staining (Figure S3A). Thus, site-directed
mutagenesis indicated that two extracellular sites N118 and N136
are glycosylated.
N-Glycosylation of CD95 does not play an essential role
for caspase-8 activation at the DISC
Having received evidence for a possible N-glycosylation at
positions N118 and N136, we next addressed the influence of
CD95 glycans on CD95 DISC formation. We therefore generated
HeLa cell lines stably overexpressing WT CD95 (HeLa-CD95
cells) as well as different CD95 glycomutants (HeLa-CD95-
N118Q, HeLa-CD95-N136Q, HeLa-CD95-T214Q, HeLa-
CD95-N223Q cells). The level of endogenous CD95 was
approximately 10 times lower than that of overexpressed WT
CD95 as estimated by quantitative Western blot by Neumann and
co-authors [26] (Figure 5A).
Plasma membrane targeting of CD95 is important for proper
CD95/CD95L interactions and transduction of the apoptotic
signal as shown earlier. In the generated stable HeLa-CD95 cell
lines, CD95 appeared to be transported to the cell surface as
monitored by flow cytometry cell surface staining (Figure S3B).
Additional evidence for cell surface expression came from the
confocal microscopy analysis of cellular compartmentalization of
CD95 glycomutants. In these experiments CD95 glycomutants as
well as WT CD95 could be observed on the plasma membrane
(Figure 5B). These results confirmed that a CD95 containing
mutation at individual glycosylation sites was translocated to the
cellular membrane. In addition, we analyzed the stability of the
glycomutants, i. e. N118Q, N136Q and N118Q/N136Q, using the
inhibitor of translation, cyclohexamide (CHX) (Figure S3C). We
did not observe any difference in the stability of CD95
glycomutants vs. WT CD95.
To analyze CD95 DISC formation and caspase-8 activation
upon deglycosylation of CD95, HeLa-CD95 cells as well as
Figure 3. Analysis of CD95 glycosylation. (A) CD95 protein
patterns were analyzed in the total cellular lysates of SKW6.4, Hut78,
J27, JA3, CEM and J16 cells on 10% SDS-PAGE followed by Western Blot
with anti-CD95 polyclonal antibodies C20. Two CD95 bands are
indicated by black arrows, while one CD95 band is indicated by a grey
arrow. (B) CD95 was immunoprecipitated from SKW6.4, J27 and JA3 cell
lysates using anti-APO-1 antibodies. CD95-immunoprecipitates (CD95-
IP) were subjected to N-glycosidase F (NGF) treatment with subsequent
analysis by Western Blot with anti-CD95 polyclonal antibodies C20. Anti-
APO-1 antibody alone was loaded on the same gel to control for the
IgG bands (lane: control). Glycosylated bands of CD95 are indicated by
black arrows, while deglycosylated bands are indicated by grey arrows.
The band corresponding to the antibody chain is indicated. After
enzymatic treatment with NGF the CD95 pattern was changed. In the
case of the SKW6.4 cells the lower band of the CD95 pattern overlaps
with the IgGl upon deglycosylation.
doi:10.1371/journal.pone.0019927.g003
Figure 2. In silico modeling of the CD95 DISC and interactions of CD95 glycosylated residues. (A) Formation of CD95-CD95L trimer upon
binding of CD95 ECDs to the CD95L ECDs trimer. (B) Close up on the interface between CD95 and CD95L ECDs. The glycan attached to N136 is in
close proximity to CD95L. The glycan attached to N118 of CD95 is distal from the CD95L ECD. (C) The glycan attached to N136 of CD95 is in a close
proximity to CD95L ECD and could form extensive hydrogen bonds (green dotted lines) with residues 200–204 of CD95L.
doi:10.1371/journal.pone.0019927.g002
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agonistic anti-APO-1-antibodies and the CD95 DISCs were
immunoprecipitated and analyzed [27]. Analysis of the CD95
DISCs demonstrated that disruption of glycosylation by mutation
(N118Q) did not influence FADD recruitment to the DISC
(Figure 5C). The introduction of mutation at N136 also did not
influence recruitment of FADD to the DISC (data not shown).
However, we observed that procaspase-8a/b processing to its
cleavage products p43/p41 and p18 at the DISC formed with the
CD95-N118Q mutant occurred slightly slower than with WT
CD95 (Figure 5C). After 10 min there was hardly any p18
detectable in HeLa-CD95-N118Q cells in comparison to HeLa-
CD95 cells, even though the amount of immunoprecipitated
CD95 was higher in HeLa-CD95-N118Q cells. This could not
result from different affinities of WT CD95 and CD95-N118Q to
anti-APO-1 antibodies because the affinity as demonstrated by
ELISA analysis was similar for both WT and mutant (Figure
S3D). Thus, we observed slower kinetics of procaspase-8
activation at the CD95 DISC in HeLa-CD95-N118Q cells.
The experiments in HeLa cells stably transfected with CD95
glycomutants show that the disruption of glycosylation did not
influence CD95 DISC formation, the recruitment of FADD to
the DISC and only slightly slowed down procaspase-8 activation
at the CD95 DISC.
To rule out that effects of deglycosylation of CD95 on caspase-8
activation have more impact upon the application of another
stimuli of CD95, e.g. via CD95L, caspase-8 activation was
compared upon stimulation with CD95L and anti-APO-1
antibodies. These experiments were carried out upon transient
overexpression of WT CD95, N118Q, N136Q and N118Q/
N136Q in HeLa cells (Figure S3E, F, G). Also CD95L also did not
cause any significant increase or decrease of caspase-8 activation in
glycomutant -transfected HeLa cells as compared to WT CD95-
transfected HeLa cells.
Finally, as a number of reports [28] show the importance of
stable, high molecular weight CD95 complexes for the efficient
activation of caspase-8, we have analyzed whether these
aggregates are perturbed after CD95 deglycosylation. We
observed the formation of the high molecular weight complexes
upon anti-APO-1 stimulation for HeLa cells with WT CD95,
N118Q, N136Q and N118Q/N136Q (Figure S3H). Therefore,
we have concluded that CD95 deglycosylation does not influence
formation of these CD95 high molecular weight structures.
Nevertheless, the analysis of CD95 DISC in HeLa cells stably
transfected with CD95 glycomutants has clear limitations due to
the presence of endogenous CD95 albeit in lower amounts.
Assessment of the effects induced by residual amounts of
endogenous CD95 on DISC formation and caspase activation
was not possible by this approach. Therefore, to analyze the CD95
DISC formation upon perturbation of CD95 N-glycosylation by
other independent approaches cells were treated with VCN
(recombinant Vibrio cholerae neuraminidase) and different inhibitors
of N-glycosylation. This was followed by analysis of the DISC
formation.
VCN preferentially hydrolyzes linkages of sialic acid (Figure
S2C). Treatment with VCN for one hour resulted in substantial
desialylation of CD95 glycans, monitored by the shift to a lower
molecular mass for both bands of CD95 (Figure 6A). To analyze
CD95 DISC formation, CD95 DISCs were immunoprecipitated
from untreated and VCN-treated SKW6.4 and Hut78 cells
(Figure 6B). The CD95 DISC formed after VCN treatment had
Figure 5. Analysis of HeLa-CD95 stable cell lines with CD95
glycosylation mutants. (A) CD95 protein pattern in cell lines stably
expressing CD95 forms was analyzed by Western Blot analysis using
anti-CD95 polyclonal antibodies C20. WT CD95 bands are indicated by
black arrows, while CD95 bands from glycomutants are indicated by
grey arrows. (B) HeLa cells stably transfected with WT CD95 and CD95
glycomutants were plated on glass slides, fixed, stained with anti-APO-1
antibodies for CD95, with anti-calreticulin for specific ER marker and
with anti-GM130 for specific Golgi marker antibodies. Localization of
CD95 was visualized by Alexa594-coupled secondary antibodies and
localization of GM130 and calreticulin was visualized by Alexa488-
coupled antibodies. Nuclei were stained with DAPI. (C) CD95 DISCs were
analyzed after treatment with 500 ng/ml of anti-APO-1 antibodies for
indicated time points. Western Blot analysis of the DISCs was performed
with antibodies against CD95, procaspase-8 and FADD. CD95 bands in
stably transfected HeLa-CD95 cells are indicated by black arrows, while
for HeLa- CD95N118Q cells CD95 bands are indicated by grey arrows.
doi:10.1371/journal.pone.0019927.g005
Figure 4. Analysis of CD95 glycosylation mutants. (A) Schematic overview of all generated glycomutants. (B) Expression of CD95 glycomutants
in HeLa cells. CD95 pattern was analyzed by Western Blot using anti-CD95 polyclonal antibodies C20. WT CD95 bands are indicated by black arrows,
while CD95 bands from glycomutants are indicated by grey arrows. (C) CD95 pattern in HeLa cells transfected with WT CD95 and CD95 glycomutants
after N-glycosidase F treatment was analyzed by Western Blot using anti-CD95 polyclonal antibodies C20.
doi:10.1371/journal.pone.0019927.g004
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and the cleavage product of c-FLIPL, p43-FLIPL (Figure 6B).
To rule out that the reduced DISC formation after VCN
treatment was not due to the decreased affinity of anti-APO-1
antibodies to desialylated CD95, we carried out an ELISA analysis
and found that the binding of desialyated and sialylated CD95 to
anti-APO-1 antibodies was similar (Figure S4A). In addition, no
change of cell surface expression of CD95 was detected (Figure
S4B). Thus, the diminished DISC formation was the consequence
of VCN treatment.
We also tried to analyze CD95 DISC formation upon treatment
with tunicamycin, an inhibitor of N-glycosylation that acts at the
ER level blocking N-glycosylation (Figure S2D). However, the
tunicamycin-induced N-deglycosylation was also accompanied by
ER stress and inhibition of translation. This led to a decrease in c-
FLIP levels, which are the main inhibitors of caspase-8 activation
at the DISC. Therefore, the decrease in caspase-8 activation at the
DISC could not be attributed to N-deglycosylation as the only
cause (Figure S5A–C and data not shown).
Finally, we also applied deoxymannojirimycin (DMM), a
reagent that inhibits the ER mannosidases and Golgi mannosidase
I, resulting in the accumulation of high-mannose oligosaccharide
structures (Figure S2E). DMM treatment resulted in a shift to the
lower molecular mass for both bands of CD95 in SKW6.4 cells
pointing to the impairment of CD95 glycostructure (Figure 7A).
Tunicamycin-treated cells were used in parallel to control CD95
band shifts. In DMM-treated cells CD95 was transported to the
cell surface as shown by surface staining (Figure S6). Stimulation of
CD95 with anti-APO-1 in DMM-treated cells resulted in
decreased amounts of FADD at the DISC and diminished
amounts of procaspase-8a/b processed at the CD95 DISC
(Figure 7A).
Taken together, we showed that CD95 DISC is formed despite
N-deglycosylation of CD95. Apparently N-deglycosylation of
CD95 reduces the amount of active caspase-8 generated at the
DISC.
Deglycosylation of CD95 leads to decreased cell death
under low strength CD95 stimulation conditions
After investigating procaspase-8 activation at the DISC we
wanted to understand the contribution of CD95 N-glycosylation to
the onset of apoptosis. The analysis of cell death upon CD95
deglycosylation has been complicated in the stable HeLa-CD95
cells as they contain endogenous CD95. The application of VCN
and tunicamycin demonstrated that they alone were already toxic
to the cells causing caspase activation and cell death (Figure S4C,
D; Figure S5D, E and data not shown). As an alternative we also
applied deoxymannojirimycin (DMM), a reagent with minimal
toxicity to the cells [29]. Our experiments demonstrated that
DMM treatment alone did not result in any cell death (Figure 7B).
Interestingly, we observed that pretreatment with DMM caused a
decrease in CD95-induced apoptosis upon stimulation with low
amounts of CD95 agonists, e.g. anti-APO-1 and CD95L (Figure 7B
and C). Upon stimulation with a high amount of CD95 agonists
we did not observe any contribution of DMM pretreatment. This
might be due to the fact that CD95 deglycosylation results in a
small decrease of procaspase-8 processing at the DISC, which does
not lead to significant effects on apoptosis provided the strength of
stimuli and the rate of apoptosis are high. However, when the
strength of stimulation is close to the threshold amount [5,30] and
the quantity of active caspase-8 generated at the DISC is low then
alterations in caspase-8 amount can result in changes in the cell
death level.
Discussion
CD95-mediated apoptosis is one of the best-studied apoptotic
signaling pathways. A number of studies have clarified the main
CD95-mediated events: DISC formation, procaspase-8 activation
and signaling in Type I and Type II cells [1,31]. Despite this
progress there are still many unknown details in the molecular
mechanisms of CD95 signal transduction. In this study we aimed
to understand the role of CD95 N-glycosylation in CD95
apoptotic signaling.
Using bioinformatic analysis we predicted the putative CD95 N-
glycosylation sites at N118 and N136, which was confirmed by
site-directed mutagenesis. In silico computer modeling showed that
CD95 N-glycosylation might play a significant role in fine-tuning
of the CD95 DISC complex. The modeling predicted that N136
may play an important role for CD95L/CD95 interactions and
that N118 might be important for stabilization of the CD95 DISC
network. Using biochemical analysis of the CD95 DISC on the
HeLa-CD95 cells and cells treated with VCN and DMM we
demonstrated that N-deglycosylation of CD95 slightly diminishes
activation of procaspase-8 at the DISC. As we observed only small
Figure 6. Analysis of CD95 DISC in cells treated with Vibrio
cholerae Neuraminidase (VCN). (A) SKW6.4 and Hut78 cells were
treated with VCN for 1 hour at 37uC. Total cellular lysates were analyzed
using Western Blot with polyclonal antibodies C20. (B) SKW6.4 and
Hut78 cells were treated with VCN for 1 hour at 37uC. CD95 DISCs were
analyzed after treatment with 1 mg/ml of anti-APO-1 antibodies for
indicated time points. Western Blot analysis of the DISCs was performed
with antibodies against CD95, procaspase-8 and c-FLIP. CD95 bands in
untreated cells are indicated by black arrows, while shifts of CD95
bands in VCN-treated cells are indicated by grey arrows.
doi:10.1371/journal.pone.0019927.g006
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DMM, which likely involves both N118 and N136, we did not
follow the contribution of each residue, e.g. N118 or N136. From
the modeling data we can suggest that both residues contribute to
the decrease in procaspase-8 activation. Similar data were
obtained upon deglycosylation of TRAIL-R by Wagner et al.
[24]. Deglycosylation of TRAIL-R1 and TRAIL-R2 led to the
diminished amounts of FADD and procaspase-8 at the TRAIL
DISC, however, the effects were more drastic than upon
deglycosylation of CD95 [24].
In contrast to the DISC analysis with N-deglycosylated CD95 it
was more difficult to establish the optimal system for the analysis of
the cell death. DMM treatment did not cause any toxicity to the
cells, therefore, represented a reliable tool for the analysis of cell
death mediated via deglycosylated CD95. We have found a
reduction of CD95-induced apoptosis upon DMM pretreatment
and low CD95 stimulation strength. This result corresponds quite
well with the slightly diminished rate of procaspase-8 activation at
deglycosylated CD95. These small kinetic effects could not
dramatically change the outcome of cell death when the strength
of CD95 stimulation was high. However, upon so-called threshold
CD95 stimulation with low doses of CD95 antagonists [5,30] the
amount of CD95 DISCs formed is low and the amount of caspase-
8 is just sufficient to trigger apoptosis [5,30]. Therefore, a decrease
in the amount of caspase-8 caused by deglycosylation of CD95
might result in apoptosis inhibition. Interestingly, deglycosylation
of TRAIL-R1 and TRAIL-R2 results in more robust sensitisation
towards apoptosis in contrast to CD95 deglycosylation. In the
latter case the observed effects took place only under the narrow
range of anti-CD95 concentrations.
Other methods of CD95 deglycosylation were found to be not
appropriate for comparison of cell death mediated by N-
deglycosylated CD95 and N-glycosylated CD95. HeLa-CD95
stable cell lines with different glycomutants contain endogenous
CD95, which did not allow us to assess the contribution of only
deglycosylated CD95 apoptosis induction. Tunicamycin induces a
number of side effects, e.g. ER-stress and translation inhibition,
that are toxic to the cells. The action of VCN resulted in the
induction of CD95-independent cell death, complicating the
analysis of CD95-induced apoptosis upon VCN action.
Interestingly, we have detected different forms of CD95 in
various cell lines, which we showed not to be the result of
differential N-glycosylation (Figure 2B, C). In some cells CD95
appears at Western Blots as two forms, 45 and 54 kDa. In other
cells only one form, of appr. 50 kDa, is observed. Interestingly,
most Type I cells, e.g. SKW6.4, Hut78 and BJAB, have two CD95
forms with a differential molecular mass of 9 kDa and Type II
cells, e.g. Jurkat and CEM cells, mostly have one CD95 form. The
nature of these forms is poorly understood. There might be two
reasons for the presence of different receptor forms – alternative
splicing and posttranslational modifications. We have shown that
alternative splicing is not the reason for the presence of several
CD95 protein forms in the cell lines under investigation (data not
shown).
Several posttranslational modifications, e.g. N-glycosylation,
proteolysis, C-mannosylation and palmitoylation, might lead to
the significant shift in molecular mass of about 9 kDa and give rise
to different forms of CD95. N-glycosylation was ruled out by our
initial experiments. Treatment with N-glycosidase F showed that
both CD95 forms shifted to a lower molecular mass. This is an
important result as there are many reports which describe the
different CD95 forms as a result of differential N-glycosylation
[18,26]. To analyze the possibility of C-mannosylation and
palmitoylation we have performed bioinformatic analysis. This
did not reveal any potential C-mannosylation sites with a
probability score higher than 0.5 (data not shown) but demon-
strated several potential palmitoylation sites. Recently, there has
Figure 7. Analysis of the role of complex and hybrid glycans in
CD95 signaling with DMM. (A) SKW6.4 were treated for 24 h with
2 mM DMM or 2 mg/ml of tunicamycin (Tuni) or left untreated. CD95
DISCs upon were analyzed after treatment with 500 ng/ml of anti-APO-
1 antibodies for 15 min. Western Blot analysis of the DISCs was
performed with antibodies against CD95, FADD and procaspase-8. IgG
Western Blot was used as a loading control for immunoprecipitation.
CD95 bands in non-treated cells are indicated by black arrows, while
CD95 bands in DMM-treated cells are indicated by grey arrows. (B) and
(C) Apoptotic cell death was measured with propidium iodide staining
in SKW6.4 cells.
doi:10.1371/journal.pone.0019927.g007
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palmitoylation facilitates apoptosis induction [28]. However,
palmitoylation of the protein does not result in a large difference
in relative molecular mass using gel electrophoretic separation
techniques and cells carrying mutations in the CD95 palmitoy-
lated site did not have an altered mobility in SDS-PAGE [28].
This rules out the possibility that palmitoylation contributes to the
generation of two forms of CD95. The possibility of proteolysis by
the metalloproteinase matrilysin (MMP7) was also excluded as the
reported cleavage of the extracellular domain of CD95 by MMP7
generates a small fragment of only one kDa [32]. The difference in
molecular mass of the two CD95 forms is about 9 kDa, which
excludes their generation by MMP7. However, we could not
exclude proteolysis mediated by other proteinases as a possible
reason for several forms of CD95 in some cell types. This question
has to be addressed in future studies.
Recently, it has been reported that O-glycosylation of
TRAILR1 (DR4) and TRAILR2 (DR5) plays a central role in
regulation of sensitivity and resistance of cells towards TRAIL-
induced apoptosis [24]. In our study we found that the only
predicted O-glycosylation site in CD95 (T214) was not glycosy-
lated. CD95 glycomutant T214Q showed the same CD95 protein
pattern upon SDS-PAGE analysis as WT CD95. The glycosyla-
tion on T214Q was highly unlikely, as it is located in the
intracellular domain. Another important result of our studies, as
mentioned above, is that the influence of CD95 glycostructure on
the apoptosis onset is less drastic than that for the TRAIL system.
This might result from the different spatial organisation of the
receptor complexes.
Taken together, using in silico modeling predictions together
with biochemical approaches, we showed that glycostructure of
CD95 can modulate procaspase-8 activation at the DISC.
Furthermore, our findings provide evidence that the CD95
glycostructure contributes to the apoptotic signaling threshold
defining cell death initiation. This may be additionally affected by
different glycostructures. This regulation might be very important
for cancer cells where subtle differences in the amount of caspase-8
regulate life or death of the cells.
Materials and Methods
Cell lines
The B lymphoblastoid cell lines SKW6.4 [33], BJAB [34] and
the T cell lines Hut78 [35], CEM [36], Jurkat A3 [37], Jurkat 16
[38], Jurkat 27 [39] were maintained in RPMI 1640 (Life
Technologies, Germany), 10 mM HEPES (Life Technologies,
Germany), 50 mg/ml Gentamycin (Life Technologies, Germany)
and 10% fetal calf serum (Life Technologies, Germany) in 5%
CO2. HeLa [40] and HEK293T [41] cell lines were maintained in
DMEM (Life Technologies, Germany), 0.5% Penicillin-Strepto-
mycin (Life Technologies, Germany) and 10% fetal calf serum
(Life Technologies, Germany) in 5% CO2.
Antibodies and reagents
Anti-CD95 polyclonal antibodies C20 were purchased from
Santa Cruz Biotechnology (Heidelberg, Germany). The anti-
FADD mAb 1C4 (mouse IgG1) recognizes the C-terminus of
FADD [42]. The anti-FLIP mAb NF6 (mouse IgG1) recognizes
the N-terminus of FLIP [43]. The anti-caspase-8 mAb C15 (mouse
IgG2b) recognizes the p18 subunit of caspase-8 [11]. Anti-APO-1
is an agonistic monoclonal antibody recognizing an epitope on the
extracellular part of CD95 (APO-1/Fas) [4]. Anti-tubulin
antibodies were purchased from Sigma. Anti-ERK antibodies
were from BD Transduction Laboratories. Anti-JNK antibodies
were purchased from Santa-Cruz Biotechnology. Horseradish
peroxidase-conjugated goat anti-mouse IgG1, -2a and -2b were
from Southern Biotechnology Associates (United Kingdom). The
coding sequence of LZ-CD95L [44] was cloned into a pIRE-
Spuro3 plasmid (Clontech, France). Recombinant LZ-CD95L was
produced using 293T cells stably transfected with this vector.
Tunicamycin and DMM were purchased from Calbiochem
(Darmstadt, Germany); VCN was from Sigma-Aldrich (Germany).
N-glycosidase F was from Roche (Mannheim, Germany). CHX
was from Sigma (Germany). pKEX plasmid was published in [45].
All other chemicals used were of analytical grade and purchased
from Merck (Germany) or Sigma (Germany).
Flow Cytometry analysis
The percentage of viable cells was determined by FSC/SSC
and propidium iodide staining using a FACScallibur Cytometer
(BD). A minimum of 10000 cells per sample was analyzed.
Surface staining. To analyze the surface expression of
CD95, 5610
5 cells were resuspended in 100 ml of FACS buffer
(10% FCS in PBS) and incubated with 10 mg/ml of anti-APO-1
antibodies or with FII23 antibodies as isotype control for 15 min
on ice. The cells were washed with FACS buffer, centrifuged and
resuspended in 100 ml of FACS buffer containing PE-conjugated
anti-mouse IgG antibody and incubated on ice for 15 min. The
cells were washed with FACS buffer and resuspended in 300 mlo f
FACS buffer containing 1 mg/ml PI. The staining was analyzed by
flow cytometry. The population was gated on living cells and the
staining of isotype control was compared to the surface staining
with anti-APO-1 antibody.
Preparation of total cellular lysates
1610
8 or 1610
6 cells were washed twice in 16 PBS and
subsequently lysed in the lysis buffer (20 mM Tris/HCl, pH 7.5,
150 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride (Sigma, Germany), protease inhibitor cocktail (Roche,
Switzerland), 1% Triton X-100 (Serva, Germany) and 10%
glycerol) (stimulation condition) or lysed without treatment
(unstimulated). The total cellular lysates were subsequently
analyzed by Western Blot.
DISC analysis by immunoprecipitation and Western Blot
1610
8 cells were treated with 1 mg/ml of anti-APO-1 antibodies
at 37uC for indicated periods of time, washed twice in 16PBS and
subsequently lysed in the lysis buffer (stimulation condition) or
lysed without treatment (unstimulated). The CD95 DISC was
immunoprecipitated overnight with 2 mg of anti-APO-1 and
protein A sepharose beads. Protein A sepharose beads were
washed five times with 20 volumes of lysis buffer. The
immunoprecipitates were analyzed on 12% PAAG. Subsequently,
the gels were transferred to Hybond nitrocellulose membrane
(Amersham Pharmacia Biotech., Germany), blocked with 5%
nonfat dry milk in PBS/Tween (PBS plus 0.05% Tween 20) for
1 h, washed with PBS/Tween, and incubated with the primary
antibodies in PBS/Tween at 4uC overnight. Blots were developed
with a chemoluminescence method following the manufacturer’s
protocol (Perkin Elmer Life Sciences, Germany).
Glycosidase treatment
For desialylation, 1610
7 cells were washed twice in 16PBS and
then treated with 100 mU VCN in RPMI, pH 6.8 for 1 hour at
37uC. For N-glycosidase F treatment 10
7 cells were lysed in buffer
A and, subsequently the total cellular lysates were treated with N-
glycosidase F following the protocol by the manufacturer.
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To completely inhibit N-linked glycosylation cells were cultured
for 20 hours in medium containing 2 mg/ml of tunicamycin. For
inhibition of mannosidase-1 cells were cultured for 48 hours in
medium containing 2 mM DMM.
Inhibition of translation
For inhibition of protein translation cells were cultured for 0, 3
and 9 hours in medium containing 10 mg/ml of CHX.
Enzyme-linked immunosorbent assay (ELISA)
Flexible 96-well plates from Becton Dickinson (USA) were
coated with 100 ml of anti-CD95 (Abcam) antibody in 0.05 M
carbonate-bicarbonate buffer pH 9.6 (CBB) at 4uC overnight.
Then the plates were washed 3 times with distilled water, blocked
with 200 ml of PBS containing 3% bovine serum albumin (BSA) at
RT for 2 hours, which was followed by washing 3 times with PBS
containing 0.5% Tween 20 (PBS-T). 100 ml of total cell lysates
were added to each well, which was followed by incubation at RT
for 1 h. After incubation, the plates were washed 3 times with
PBS-T. This was followed by addition of 100 ml of peroxidase-
conjugated goat anti-mouse IgG antibody (Jackson ImmunoR-
esearch Laboratories) diluted at 1/5000 in PBS-1% BSA. The
plates were incubated for 1 h at 4uC. After incubation, the plates
were washed 3 times with PBS-T and then the reaction was
revealed with 100 ml of OPD 0.4 mg/ml (Sigma) in 0.05 M
phosphate-citrate buffer, pH 5.0 solution for 10–20 min at room
temperature. After stopping the reaction with 100 mlo f3 N
H2SO4, the plates were read with an ELISA reader (Wallac,
Gaithersburg, USA) at 490 nm.
Homology modeling and structures visualization
Modeling was carried out as previously described in [46,47]
using the MODELLER package [48]. Human CD95 ECD was
modeled using crystal structures of tumor necrosis factor receptor
(PDB ID 1ncf [49] and 1tnr.R [50]) as the templates. The CD95
transmembrane region was modeled as an a-helix bases on the
prediction of the TMHMM Server v. 2.0 (www.cbs.dtu.dk/
services/TMHMM/). To model free full-length CD95 receptor as
envisaged on a plasma membrane the CD95 ECD and TM
domains were modeled as described above and the model of CD95
DD domain was based on the NMR structure of CD95 DD in
solution (PDB ID 1ddf, [51]) added. Human CD95L ECD was
modeled using the crystal structure of tumor necrosis factor beta
(PDB ID 1tnr.A [50]) as the template. The model of the complete
CD95 DISC core structure was assembled on the crystal structure
of Apo2L/TRAIL in a complex with death receptor 5 (PDB ID
1dog [52]): CD95 ECD and TM domains were modeled as
described above and the model of the CD95 DD domain was
based on the CD95 DD crystal structure from the CD95/FADD
DDs complex (PDB ID 3ezq [16]). As their precise composition
and structure is unknown, only core structures of N-glycans were
added using GlyProt [53]. GROMACS [54] molecular dynamics
and the quality analysis (ANOLEA [55], VERIFY_3D and
ERRAT [http://nihserver.mbi.ucla.edu/]) and visualization/
analysis (SwissPBD Viewer [56] and PyMol [www.pymol.org])
tools were employed as described in details in [46,47] use instead
[57].
Supporting Information
Figure S1 Alignment of CD95 sequences from different
organisms. (A) ClustalX2 sequence alignment of CD95 ECD
across different species. Sequence abbreviations: Homo sapiens
(HUMAN); Macaca fascicularis (MACFA); Macaca nemestrina
(MACNE); Cercocebus torquatus (CERTO); Macaca mulatta
(MACMU); Macaca arctoides (MACAR); Macaca assamensis
(MACAS); Aotus trivirgatus (AOTTR); Callithrix jacchus
(CALJA); Oryctolagus cuniculus (RABIT); Sus scrofa (PIG); Ovis
aries (SHEEP); Felis catus (FELCA); Bos taurus (BOVIN); Mus
musculus (MOUSE) and Rattus norvegicus (RAT). Sequences
from NCBI Protein databank. Color lines on the top of the
alignment indicate cysteine residues forming disulphide bonds in
human CD95. N-X-S/T sequons are indicated by red boxes. (B)
Probability of glycosylation (glycosylation potential) of sequons at
positions 118 and 136 in human CD95 and their analogues in
CD95 from other species was calculated by NetNGlyc 1.0 server.
(TIF)
Figure S2 Schematic mechanisms of enzymatic and
inhibitory deglycosylation. (A) Core structure of N-glycan
added to the models is a minimal possible composition of N-
glycans. (B) The mechanism of action of N-glycosidase F. Variable
structures of glycan side chains are presented in grey. (C) The
mechanism of action of tunicamycin. Variable structures of glycan
side chains are presented in grey. (D) The mechanism of action of
VCN. Variable structures of glycan side chains are presented in
grey. (E) The mechanism of action of DMM. Variable structures
of glycan side chains are presented in grey.
(TIF)
Figure S3 Analysis of CD95 glycosylation mutants. (A)
Cell surface staining of WT CD95 and CD95 glycomutants for
transiently transfected HeLa cells was performed with anti-APO-1
IgG3 antibodies (red line). As isotype control FII23C IgG3
antibodies were used (Black and violet lines). To control efficiency
of CD95 surface expression HeLa-CD95 stable cell line was used
(green line). (B) Cell surface staining of WT CD95 and CD95
glycomutants in stable cell lines was performed with anti-APO-1
IgG3 antibodies. As isotype control FII23C IgG3 antibodies were
used. (C) Degradation of WT CD95 and CD95 glycomutants in
transiently transfected HEK293T cells was performed upon
treatment with CHX. Total cellular lysates were analyzed after
treatment with CHX using Western Blot with polyclonal
antibodies C20, monoclonal NF6 antibodies against FLIP and
anti-tubulin antibodies.(D) Binding of CD95 WT and glycomu-
tants to anti-APO-1 antibodies. Cellular lysates from the HeLa
cells stably transfected with CD95 WT and glycomutants were
used for anti-APO-1-specific ELISA analysis. Anti-APO-1 was
used in concentrations. 0.1, 0.2, 0.4, 0.8 and 1 mg/ml. (E) and (F).
Comparison of caspase-8 activation was performed upon treat-
ment with CD95L or anti-APO-1. To control activation of
caspase-8 transiently transfected with WT CD95 and CD95
glycomutants HeLa cells were stimulated with CD95L or anti-
APO-1 for indicated time points. Total cellular lysates were
analyzed using Western Blot with C15 monoclonal antibodies for
caspase-8 and anti-tubulin antibodies. (G). Control of CD95
expression for (E) and (F) was done after immunoprecipitation with
anti-APO-1 by Western Blot with C20 polyclonal antibodies. (H).
The ability to form CD95n oligomeric structures was compared
between WT CD95 and CD95 glycomutants. Analysis was done
by Western Blot with polyclonal C20 antibodies and anti-ERK
antibodies. In the (C), (G) and (H) WT CD95 bands are indicated
by black arrows, while CD95 bands from glycomutants are
indicated by grey arrows. CD95n oligomeric structures are
indicated by red arrow.
(TIF)
Figure S4 Analysis of deglycosylation of CD95 with
VCN. (A) ELISA analysis for the binding of anti-APO-1
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treated SKW6.4 cells. (B) Cell surface staining of untreated and
VCN-treated SKW6.4 cells was performed with anti-APO-1 IgG3
antibodies. As isotype control FII23C IgG3 antibodies were used.
(C) Caspase-3 processing and Bid cleavage were analyzed in
untreated and VCN-treated SKW6.4 cells using Western Blot. (D)
SKW6.4 cells were treated as it was described in A and cell death
was measured with propidium iodide staining.
(TIF)
Figure S5 Analysis of CD95 N-glycosylation with tuni-
camycin. (A) SKW6.4 and Hut78 cells were treated for 24 h with
2 mg/ml of tunicamycin (Tuni) or left untreated. CD95 DISCs
were analyzed after stimulation with 500 ng/ml of anti-APO-1
antibodies for indicated time points. Western Blot analysis of the
DISCs was performed with antibodies against CD95, procaspase-8
and c-FLIP. CD95 bands in non-treated cells are indicated by
black arrows, while shifts of CD95 bands in tunicamycin-treated
cells are indicated by grey arrows. (B) Cell surface staining of
CD95 was performed with anti-APO-1 IgG3 antibodies. As
isotype control FII23C IgG3 antibodies were used. (C) C-FLIP
expression was analyzed by Western Blot analysis using monoclo-
nal NF6 antibodies. (D) SKW6.4 and Hut78 cells were treated for
24 h with 2 mg/ml of tunicamycin (Tuni) or left untreated. Total
cellular lysates were analyzed after treatment with 1 mg/ml of anti-
APO-1 antibodies using Western Blot with polyclonal antibodies
C20 and monoclonal antibodies C15 against procaspase-8. Anti-
JNK1 Western Blot was used as a loading control. (E) SKW6.4
cells were treated as was described in A and apoptotic cell death
was measured with propidium iodide staining.
(TIF)
Figure S6 The analysis of deglycosylation of CD95 with
DMM. (A) Cell surface staining of CD95 was performed with
anti-APO-1 IgG3 antibodies. As isotype control FII23C IgG3
antibodies were used.
(TIF)
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